Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
WGU55
- Development stage
- Unknown
- Lead developer
- Université de Sherbrooke
01
Overview
WGU55: sourced facts only. name: "Notably, WGU55 showed exceptional selectivity toward TMPRSS6 over matriptase and minimal off-target inhibition of coagulation serine proteases such as Factor Xa and Thrombin, representing, to our knowledge, the most selective TMPRSS6 inhibitor identified to date." [PMID:41349957]; target: "Notably, WGU55 showed exceptional selectivity toward TMPRSS6 over matriptase and minimal off-target inhibition of coagulation serine proteases such as Factor Xa and Thrombin, representing, to our knowledge, the most selective TMPRSS6 inhibitor identified to date." [PMID:41349957]; developer: "Department of Pharmacology-Physiology, Faculty of Medicine and Health Sciences, Université de Sherbrooke, Sherbrooke, Québec, Canada J1H 5N4." [PMID:41349957]
02
Targets
TMPRSS6 (Transmembrane Serine Protease 6)
Beyond the preview
Go deeper on WGU55.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on WGU55.